Deplatt a 150
Reading File
Finding Sources
Searching PubMed
clopidogrel aspirin dual antiplatelet therapy
Searching the Web
Deplatt A 150 clopidogrel aspirin uses dosage indications
Reading File
Reading File
Deplatt A 150
Deplatt A 150 is a fixed-dose combination tablet manufactured by Torrent Pharmaceuticals containing:
- Clopidogrel 75 mg + Aspirin 150 mg
Composition & Mechanism
| Component | Class | Mechanism |
|---|---|---|
| Clopidogrel 75 mg | P2Y12 receptor antagonist (thienopyridine) | Irreversibly blocks ADP receptors on platelets, inhibiting ADP-mediated platelet aggregation |
| Aspirin 150 mg | COX-1 inhibitor (NSAID) | Irreversibly inhibits cyclooxygenase-1, preventing thromboxane A2 synthesis and platelet aggregation |
Together, they block two separate platelet activation pathways, producing synergistic antiplatelet effect - this is called Dual Antiplatelet Therapy (DAPT).
Indications
- Acute Coronary Syndrome (ACS) - unstable angina, NSTEMI, STEMI
- Post-Percutaneous Coronary Intervention (PCI) - after coronary stenting (bare-metal or drug-eluting stents)
- Recent Myocardial Infarction (MI)
- Recent Ischemic Stroke or TIA (in selected cases)
- Peripheral Arterial Disease (PAD) with high atherothrombotic risk
- Prevention of in-stent restenosis after PCI
Dosage
- Usual adult dose: 1 tablet once daily (Clopidogrel 75 mg + Aspirin 150 mg)
- Best taken with food to reduce GI side effects
- Loading dose (in ACS): Clopidogrel 300-600 mg + Aspirin 300 mg is given first, then maintenance with Deplatt A 150 once daily
Duration of Therapy (DAPT)
| Clinical Scenario | Minimum DAPT Duration |
|---|---|
| Bare-metal stent (BMS) | 3-4 weeks |
| Drug-eluting stent (DES) | Minimum 12 months |
| ACS (medically managed) | 12 months |
| Recent MI or stroke | As directed by physician |
- Textbook of Family Medicine 9e, p. 3771: "For patients receiving a drug-eluting stent, dual antiplatelet therapy needs to be continued for a minimum of 1 year."
Side Effects
Common:
- GI upset, dyspepsia, nausea
- Abdominal pain, heartburn
- Diarrhea
Serious:
- Bleeding - GI bleeding, intracranial bleed (most important risk)
- Thrombotic Thrombocytopenic Purpura (TTP) - rare, with clopidogrel
- Neutropenia - rare
- Hypersensitivity/skin rash
Contraindications
- Active pathological bleeding (peptic ulcer, intracranial hemorrhage)
- Hypersensitivity to aspirin or clopidogrel
- Severe hepatic impairment
- Third trimester of pregnancy
Important Drug Interactions
| Drug | Interaction |
|---|---|
| PPIs (especially omeprazole) | Omeprazole reduces clopidogrel efficacy (CYP2C19 inhibition); prefer pantoprazole if GI protection needed |
| NSAIDs | Increased bleeding risk |
| Warfarin/anticoagulants | Greatly increased bleeding risk; use only if clearly indicated |
| SSRIs/SNRIs | Increased GI bleed risk |
Clinical Notes
- Clopidogrel resistance occurs in ~25-30% of patients due to CYP2C19 genetic polymorphism (poor metabolizers) - these patients may benefit from prasugrel or ticagrelor instead
- Do not abruptly stop DAPT (especially post-stenting) - risk of stent thrombosis
- Use pantoprazole (not omeprazole) for GI protection alongside DAPT
- A 2025 Lancet meta-analysis (PMID 40902613) found clopidogrel monotherapy vs aspirin for secondary coronary prevention - still confirming clopidogrel's role; combination DAPT remains standard post-ACS/PCI
- A 2024 JAMA Cardiology network meta-analysis (PMID 39382876) supports short-duration DAPT after DES in ACS patients as a reasonable strategy to balance ischemic and bleeding risk
Summary
Deplatt A 150 is a standard DAPT combination used to prevent recurrent cardiovascular events. The aspirin 150 mg dose is the standard maintenance dose used in India (globally, 75-100 mg is more common). It should always be taken under medical supervision with attention to bleeding risk, GI protection, and appropriate duration based on the clinical indication.
This is a shared conversation. Sign in to Orris to start your own chat.